Monoglycosylated spike protein vaccine provides better protection against infections of SARS-CoV-2its variants of concern. Spike protein, which is the main immunogen in all current vaccines, is heavily glycosylatedthe epitopes covered by glycans are usually less immunogenic. Monoglycosylated spike protein vaccine, when vaccinated, can elicit better immune response with a more complete protection against all possible epitopes from spike polypeptide sequence,provide better protection against infections from variants of concerns.

NRICM101 has revealed positive outcome in COVID-19 treatment clinically. Pharmacological studies have confirmed that it can neutralize the SARS-CoV-2, block virus infection, inhibit virus growth,reduce the occurrence of cytokine storms. NRICM101 has been non-exclusively authorized by 8 Taiwanese GMP-certified TCM pharmaceuticals. At present, NRICM101 is seeing an increasing worldwide demand,has received Emergency Use Authorization from the Ministry of HealthWelfare of Taiwan. Asymptomaticmildly ill patients of COVID-19 are expected to benefit from it.

Our core generated several types of transgenic micea stable humanized ACE2 mice using a combi-CRISPR genetic engineering technique. We hope these mouse models can help to dissect COVID-19 pathogenic mechanismthe interaction(s) between spike proteinACE2 K353.

A virus NT was performed in a biosafety level 3 laboratory to determine the titers. A SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) was designed to detect neutralizing antibodies in the serum, based on the binding affinity of SARS-CoV-2 viral protein 1viral protein 2 to antibodies. ELISA results viral protein 12, generated comparable neutralizing antibody titers. The results analyzed by spline regressiontwo-variable generalized additive model precisely reflected the real NT value. Our method can serve as a surrogate to quantify neutralizing antibody titer.

The prevalence of olfactory dysfunction increases significantly in recent years. More than 35 patients with COVID-19 have sequelae of olfactory dysfunction after recovery. However, there are no effective treatments for sensorineural olfactory dysfunction to date. This is the first report demonstrates that chitosan can promote differentiation of olfactory receptor neuronsregenerate olfactory neuroepithelium. Further intranasal administration of chitosan will be developed for treating olfactory dysfunction.

By the help of the High Throughput Core Facility of the Genome Center of the Academia Sinica, potential drugs with activity are screened out,the P3 laboratory conducts the antiviral cell experiment of the drug to accurately determine the effect of inhibiting the virus. In addition, the production process of the antiviral drug "Remdesivir" is improved,innovative preparation methods are proposed, which greatly increase the yield of "Remdesivir"effectively reduce the manufacturing cost.

Due to the recent outbreak of COVID-19ongoing mutants, we developed a coronavirus variant protein microarray that includes all the current spike mutationsthe wild-type viral antigensapplied in detecting immune responsesdrug specificities. We filed the patientspublished our findings in the Analytical Chemistry. Besides massive production of the coronavirus protein microarray, we also collaborated with a scanner company, developed artificial intelligence software,collaborated with suppliers. We are welcome any sort of collaboration.

Ninety percent of human diseases are related to abnormal inflammation. WJM team has successfully developed a new monoclonal antibody that can inhibit a key inflammation protein. Animal experiments have accumulated more than ten disease modes, including a variety of solid tumors, fibrosis, degenerativecardiovascular diseases. This antibody is qualified as an orphan drug for the treatment of IPF. New coronary pneumonia has greatly increased the demand for pulmonary fibrosis treatment,has also become an important target for mergersacquisitions of global pharmaceutical companies.

BPRSJ338 exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19 as a first-in-class drug. BPRSJ338 also potently inhibits against broad-spectrum coronaviruses including SARS-CoV-2, SARS-CoV, HCoV-229E, HCoV-OC43, TGEV, FIPV and MHV. Related US and Taiwan patents have been granted.​ Therefore it is also applicable to fight against severe evolving coronaviruses in the future.

We have developed a low-costportable reader for thermometric lateral flow immunoassay (TLFIA) using colloidal goldlatex beads as reportersa continuous-wave green laser as the heating source. Instead of using infrared cameras, a single-element infrared sensor is employed for temperature sensing without compromising the sensitivity of the reader. The thermometric assay provides a 10× higher sensitivity than color visualizationthe results are sufficiently quantitative to support decision making in point-of-care testing for infectious diseases (such as COVID-19).

Our technology combines optimized semiconductor manufacturing technique with unique biomediator preparation to achieve the first reliable POC biosensing platform. Sensors developed according to this method possess reproducibility, accuracy,stability that meet POC. Our sensors are portable, require low sample volume, do not require sample processing,are extremely suitable for use in POC settings. They can also be integrated into IoT systems to aide in rapid decision making,can be mass produced. Overall, we are the first to achieve accessible, reliable detection at the POC.

We propose an AI dynamics drug repurposing platform applicate on COVID-19. This platform analyzed a large number of structures of SARS-CoV, MERS,cross-species coronavirus 3CL protease-ligand complexes to construct uncovering six flexible active site conformationspharmacophore clusters for SARS-CoV-2 3CL protease screening all FDA drugsfound four inhibitors within three months. Among them, JM206 had even demonstrated ten times better efficacy than Remdesivir in-vitro assayalso show the effect on the in-vivo hamster model to alleviate the symptoms caused by COVID-19.

We have designed a remotely-controlled robot which equipped with a 360 degree full HD camera. User’s postures are detected by measuring the accelerationrotation of changes of limb postures using inertial measurement units (IMU). User’s motion commands are wirelessly transmitted to actuate the remote robot in accordance with user’s posture. The 360 degree full scene camera keeps transmitting the real-time situation of the scene surrounding the robot back to the user, displayed on the VR headset.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected human cell through ACE2. This study is developing a Pd nano-thin film electrode for electrochemical impedance spectroscopy. This invention can quantify neutralize antibody too. The detection platform can be used to screen 1 microliter anti-virus infection drug sample within 21 mins. Compare to SPR standard, our invention only needs 1/10000 concentration of ACE2reaction volume is ~1/30 than SPR. This invention can be adapted in detection of cancer markers,other emergency infection diseasestherapeutic drugs, too.